BLPH Bellerophon Therapeutics Inc

BLPH - Bellerophon Therapeutics Inc

Price

$0.00

+ 0.00 (0.00%)

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Stock Chart

leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

BLPH

Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know07-06-2023 22:00:21 PM

In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $0.69, marking a -1.78% move from the previous day.

BLPH

Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know06-29-2023 22:00:24 PM

Bellerophon Therapeutics (BLPH) closed the most recent trading day at $0.68, moving -1.93% from the previous trading session.

BLPH

7 Must-Have Stocks to Buy and Hold for a Secure Future06-19-2023 10:00:34 AM

One reason we invest in the stock market is that we’re all looking to secure our financial futures. We want to be comfortable in our retirements and provide for our families and even future generations. Getting there means finding reliable buy and hold stocks for long-term portfolios. Warren Buffett, of course, is the acknowledged king of buy and hold stocks, or long-term investing. The Oracle of Omaha makes his fair share of trades, but his famed portfolio also includes many stocks he’s held fo

BLPH

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?06-06-2023 13:40:10 PM

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

BLPH

Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease06-05-2023 11:00:00 AM

Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeu

BLPH

Bellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week alone05-17-2023 10:30:39 AM

Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit...

BLPH

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results05-15-2023 20:50:00 PM

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023. “We are pleased with the prog

BLPH

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease05-11-2023 12:30:00 PM

Pivotal top-line data readout expected in mid-2023WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial l

BLPH

Bellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should Know04-28-2023 21:50:09 PM

In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $7.65, marking a +1.06% move from the previous day.

BLPH

Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?04-24-2023 15:57:03 PM

Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.